Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ABEO

Abeona Therapeutics Inc

6.98

Jul 10 • 04:00PM ET -0.14 (-1.97%)

Healthcare Biotechnology USA Small NASD

Peers: MGTX RGNX PRME SLDB DTIL VYGR ALLO HUMA BBOT CRMD

| Held by: VTI IWM VXF IWN SURI FESM VTWO IWC ITOT EES

Scroll to Statements

Index	RUT
Market Cap	397.83M
Enterprise Value	252.73M
Income	66.14M
Sales	14.54M
Book/sh	2.55
Cash/sh	2.95
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	226
IPO	Sep 19, 1980

P/E	7.45
Forward P/E	-
PEG	-
P/S	27.36
P/B	2.74
P/C	2.36
P/FCF	-
EV/EBITDA	-
EV/Sales	17.38
Quick Ratio	5.70
Current Ratio	5.89
Debt/Eq	0.16
LT Debt/Eq	0.06
Option/Short	Yes / Yes

EPS (ttm)	0.94
EPS next Y	-0.07
EPS next Q	-0.22
EPS this Y	-171.45%
EPS next Y	90.99%
EPS next 5Y	-26.72%
EPS past 3/5Y	- -
Sales past 3/5Y	60.26% -10.26%
EPS Y/Y TTM	246.52%
Sales Y/Y TTM	-
EPS Q/Q	-24.83%
Sales Q/Q	-
Earnings	May 13 BMO
EPS/Sales Surpr.	10.45% 90.72%

Insider Own	11.80%
Insider Trans	-7.45%
Inst Own	69.46%
Inst Trans	-4.32%
ROA	44.41%
ROE	70.99%
ROIC	43.08%
Gross Margin	34.60%
Oper. Margin	-637.92%
Profit Margin	454.86%
SMA20	16.23%
SMA50	21.13%
SMA200	33.44%
Trades

Shs Outstand	56.87M
Shs Float	50.27M
Short Float	27.21%
Short Ratio	11.36
Short Interest	13.68M
52W High	7.54 -7.43%
52W Low	4.00 74.50%
Volatility	6.05% 4.84%
ATR (14)	0.31
RSI (14)	72.67
Beta	1.35
Rel Volume	1.35
Avg Volume	1.20M
Volume	1,629,290

Perf Week	9.06%
Perf Month	28.07%
Perf Quarter	36.33%
Perf Half Y	33.72%
Perf YTD	32.45%
Perf Year	19.32%
Perf 3Y	71.92%
Perf 5Y	-81.87%
Perf 10Y	-88.22%
Recom	1.00
Target Price	19.71
Prev Close	7.12
Price	6.98
Change	-1.97%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	Oppenheimer	Outperform	$19
Mar-05-25	Initiated	Oppenheimer	Outperform	$16
Jul-03-24	Initiated	H.C. Wainwright	Buy	$15
May-30-24	Initiated	Stifel	Buy	$21
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23

Show Previous Ratings

Jul-01-26 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-01-26 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-26-26 08:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-13-26 07:01PM	Abeona Therapeutics Inc (ABEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
07:35AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press)
07:30AM	Loading…
07:30AM	Abeona Therapeutics Reports First Quarter 2026 Results and Provides Pipeline Update (GlobeNewswire)
May-11-26 08:30AM	Abeona Therapeutics Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN (GlobeNewswire)
May-04-26 08:30AM	Abeona Therapeutics Announces Date of First Quarter Financial Results (GlobeNewswire) +9.58%
May-01-26 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-07-26 08:30AM	Abeona Therapeutics Announces Appointment of Keith A. Goldan to its Board of Directors (GlobeNewswire)
Apr-06-26 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-26 08:30AM	Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in New York (GlobeNewswire) +5.24%
Mar-20-26 08:30AM	Abeona Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-17-26 03:02PM	Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ... (GuruFocus.com)
07:39AM	Abeona Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Loading…
07:30AM	Abeona Therapeutics Reports Full Year 2025 Financial Results and Corporate Updates (GlobeNewswire)
Mar-09-26 07:30AM	Abeona Therapeutics Provides Business Update Highlighting Building Momentum in ZEVASKYN Commercial Launch (GlobeNewswire) +6.39%
Mar-03-26 07:30AM	Abeona Therapeutics Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference (GlobeNewswire)
Feb-14-26 05:00AM	Netflix Is Casting a Light on a Rare Disease. Pearl Jam's Frontman Is Raising Cash to Cure It. (Barrons.com)
Feb-09-26 10:04AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-15-25 07:30AM	Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer (GlobeNewswire) -5.22%
Dec-11-25 07:30AM	Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in Texas (GlobeNewswire)
Dec-08-25 07:30AM	Abeona Therapeutics Announces First Patient Treatment with ZEVASKYN Gene Therapy (GlobeNewswire) +5.34%
Dec-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.72%
Nov-12-25 04:01PM	Abeona Therapeutics Inc (ABEO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +18.47% -8.30%
11:37AM	Here's Why Abeona Therapeutics Popped Higher Today (Motley Fool)
07:40AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Nov-07-25 07:30AM	Abeona Therapeutics Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation (GlobeNewswire)
07:30AM	Loading…
Nov-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-25 10:45AM	Abeona Therapeutics Announces Permanent J-Code for ZEVASKYN (prademagene zamikeracel) (GlobeNewswire)
Oct-20-25 08:30AM	Abeona Therapeutics Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs (GlobeNewswire)
Oct-13-25 07:30AM	Abeona Therapeutics Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program (GlobeNewswire)
Oct-08-25 07:30AM	Abeona Therapeutics and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN Gene Therapy (GlobeNewswire) +5.52%
Oct-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-25 10:18AM	Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor? (Zacks)
Sep-08-25 08:28AM	Should You Invest in Abeona Therapeutics (ABEO)? (Insider Monkey)
Sep-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-29-25 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 07:38AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +10.21%
07:30AM	Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Aug-11-25 06:19AM	Cell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 \| Abeona Therapeutics, CellSeed, J-TEC, and Holostem Lead with First-in-Class Therapies and Strong Commercialization Strategies (GlobeNewswire)
Aug-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 11:40PM	Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy (Insider Monkey) -6.32%
Jul-29-25 10:00AM	AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients (GlobeNewswire)
Jul-15-25 07:30AM	ZEVASKYN Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area (GlobeNewswire)
Jul-14-25 07:00AM	Bio-Techne's Simple Western Technology Utilized in Recent FDA Approval of ZEVASKYN Cell-Based Gene Therapy (PR Newswire)
Jul-02-25 07:30AM	Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million (GlobeNewswire) +5.39%
Jul-01-25 07:30AM	Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy (GlobeNewswire)
07:15AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-25 07:30AM	Abeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index (GlobeNewswire)
Jun-24-25 07:30AM	Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL Study Data in Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Jun-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 08:46AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 07:38AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +7.42%
07:30AM	Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
May-14-25 08:07AM	UPDATE -- Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
May-13-25 07:21AM	Abeona secures cash runway with $155m priority review voucher sale (Pharmaceutical Technology)
May-12-25 07:30AM	Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million (GlobeNewswire) +6.26%
04:38AM	Abeona sells speedy drug review voucher for $155M (BioPharma Dive)
May-07-25 04:59PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.51%
Apr-30-25 07:16AM	FDA approves Abeonas $3.1m cell therapy for rare skin disease (Pharmaceutical Technology) +23.77%
Apr-29-25 03:06PM	Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy (Benzinga)
06:00AM	U.S. FDA Approves ZEVASKYN (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Apr-27-25 08:30AM	Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken + (Seeking Alpha)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-14-25 07:11AM	Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside (Seeking Alpha) +7.61%
Apr-12-25 11:39AM	Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher (Seeking Alpha)
Apr-06-25 08:38AM	Krystal Biotech: Some Uncertainty, Some Value (Seeking Alpha)
Apr-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.51%
Mar-21-25 03:02AM	Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:41AM	Q4 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 03:21PM	Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations (SeekingAlpha)
03:20PM	Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:30AM	Abeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans (GlobeNewswire)
Mar-04-25 09:00AM	Abeona Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
07:46AM	Abeona Therapeutics announces new employee inducement grants (TipRanks)
Mar-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire) +6.30%
Nov-15-24 02:06AM	Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-14-24 07:42AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Nov-12-24 07:30AM	Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) -5.05%
Nov-04-24 07:30AM	Abeona Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire)
Nov-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-29-24 07:30AM	Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration (GlobeNewswire)
Oct-09-24 06:13PM	Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 07:30AM	Abeona Therapeutics Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors (GlobeNewswire)
Aug-13-24 07:30AM	Abeona Therapeutics Announces Favorable Medicare Reimbursement Decisions for Pz-cel (GlobeNewswire)
Aug-12-24 07:37AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.99%
07:30AM	Abeona Therapeutics Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission (GlobeNewswire)

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Ph.D.Dr. Vishwas Seshadri M.B.A.

Chief Financial OfficerMr. Joseph Walter Vazzano CPA

Ph.D.Dr. Brendan M. O'Malley J.D.

Chief Technical & Scientific OfficerMr. Brian Kevany Ph.D.

Vice President of Investor Relations & Corporate CommunicationsMr. Gregory Gin

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vazzano Joseph Walter	Chief Financial Officer	Jul 09 '26	Sale	6.96	24,880	173,257	493,557	Jul 09 07:24 PM
Seshadri Vishwas	Chief Executive Officer	Jul 09 '26	Sale	6.96	67,971	473,330	1,306,108	Jul 09 07:22 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jul 09 '26	Sale	6.96	12,050	83,913	427,953	Jul 09 07:20 PM
Vasanthavada Madhav	Chief Commercial Officer	Jul 09 '26	Sale	6.96	12,606	87,784	290,623	Jul 09 07:17 PM
Seshadri Vishwas	Officer	Jul 09 '26	Proposed Sale	6.96	67,971	473,330		Jul 09 04:17 PM
Vasanthavada Madhav	Officer	Jul 09 '26	Proposed Sale	6.96	12,606	87,784		Jul 09 04:15 PM
Vazzano Joseph Walter	Officer	Jul 09 '26	Proposed Sale	6.96	24,880	173,257		Jul 09 04:12 PM
O'Malley Brendan M.	Officer	Jul 09 '26	Proposed Sale	6.96	12,050	83,913		Jul 09 04:11 PM
Silverstein Christine Berni	Former Director	Jul 06 '26	Proposed Sale	6.27	102,180	640,771		Jul 06 04:12 PM
Alland Leila	Director	Jun 30 '26	Sale	5.92	11,000	65,087	162,614	Jul 02 04:30 PM
Silverstein Christine Berni	Director	Jun 15 '26	Sale	5.71	18,160	103,695	119,562	Jun 15 07:48 PM
Silverstein Christine Berni	Director	Jun 15 '26	Proposed Sale	5.71	18,160	103,695		Jun 15 04:48 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jun 09 '26	Sale	5.30	6,305	33,443	440,003	Jun 09 08:32 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jun 08 '26	Sale	5.43	4,826	26,203	446,308	Jun 09 08:32 PM
Vazzano Joseph Walter	Chief Financial Officer	Jun 09 '26	Sale	5.36	39,067	209,476	518,437	Jun 09 08:32 PM
Vazzano Joseph Walter	Chief Financial Officer	Jun 08 '26	Sale	5.43	10,271	55,766	557,504	Jun 09 08:32 PM
Vasanthavada Madhav	Chief Commercial Officer	Jun 09 '26	Sale	5.30	5,450	28,908	303,451	Jun 09 08:32 PM
Vasanthavada Madhav	Chief Commercial Officer	Jun 08 '26	Sale	5.43	4,170	22,641	308,901	Jun 09 08:32 PM
Seshadri Vishwas	Chief Executive Officer	Jun 09 '26	Sale	5.30	31,916	169,289	1,374,079	Jun 09 08:32 PM
Seshadri Vishwas	Chief Executive Officer	Jun 08 '26	Sale	5.43	24,428	132,632	1,405,995	Jun 09 08:32 PM
Vazzano Joseph Walter	Officer	Jun 09 '26	Proposed Sale	5.39	25,646	138,288		Jun 09 05:24 PM
Vasanthavada Madhav	Officer	Jun 08 '26	Proposed Sale	5.25	10,000	52,500		Jun 08 06:40 PM
O'Malley Brendan M.	Officer	Jun 08 '26	Proposed Sale	5.25	12,000	63,000		Jun 08 06:39 PM
Seshadri Vishwas	Officer	Jun 08 '26	Proposed Sale	5.25	58,000	304,500		Jun 08 06:38 PM
Vazzano Joseph Walter	Officer	Jun 08 '26	Proposed Sale	5.25	25,000	131,250		Jun 08 06:38 PM
Alvino Mark	Director	May 22 '26	Sale	5.46	6,500	35,463	77,565	May 22 05:24 PM
Alvino Mark	Director	May 22 '26	Proposed Sale	5.46	6,500	35,463		May 22 04:12 PM
Crombez Eric	Director	May 15 '26	Sale	5.53	26,143	144,636	37,313	May 15 05:00 PM
Crombez Eric	Director	May 15 '26	Proposed Sale	5.53	26,143	144,636		May 15 04:29 PM
Vasanthavada Madhav	Chief Commercial Officer	May 11 '26	Sale	5.96	5,548	33,073	313,071	May 11 06:36 PM
Vasanthavada Madhav	Officer	May 11 '26	Proposed Sale	5.96	5,548	33,073		May 11 04:16 PM
Seshadri Vishwas	Chief Executive Officer	Mar 31 '26	Sale	4.38	29,985	131,481	1,430,423	Mar 31 09:03 PM
Seshadri Vishwas	Officer	Mar 31 '26	Proposed Sale	4.38	29,985	131,481		Mar 31 04:42 PM
Vazzano Joseph Walter	Officer	Mar 16 '26	Proposed Sale	4.76	785	3,737		Mar 16 04:31 PM
Vazzano Joseph Walter	Chief Financial Officer	Mar 16 '26	Sale	4.76	785	3,737	567,775	Mar 16 04:29 PM
Silverstein Christine Berni	Director	Feb 02 '26	Proposed Sale	5.09	20,070	102,168		Feb 09 04:01 PM
Silverstein Christine Berni	Director	Feb 02 '26	Sale	5.09	20,070	102,168	137,722	Feb 04 04:30 PM
Wuchterl Donald A.	Director	Feb 02 '26	Sale	5.09	14,814	75,412	167,935	Feb 02 06:59 PM
Crombez Eric	Director	Feb 02 '26	Sale	5.09	16,284	82,895	63,456	Feb 02 06:55 PM
Wuchterl Donald A.	Director	Feb 02 '26	Proposed Sale	5.09	14,814	75,412		Feb 02 04:58 PM
Crombez Eric	Director	Feb 02 '26	Proposed Sale	5.09	16,284	82,886		Feb 02 04:43 PM
Alvino Mark	Director	Feb 02 '26	Proposed Sale	5.09	2,000	10,180		Feb 02 04:40 PM
Alland Leila	Director	Feb 02 '26	Proposed Sale	5.09	18,065	91,962		Feb 02 04:39 PM
Alland Leila	Director	Feb 02 '26	Sale	5.09	18,065	91,962	173,614	Feb 02 04:30 PM
Alvino Mark	Director	Feb 02 '26	Sale	5.09	2,000	10,181	84,065	Feb 02 04:30 PM
Vasanthavada Madhav	Chief Commercial Officer	Jan 22 '26	Sale	5.29	12,610	66,658	318,619	Jan 26 04:35 PM
Vazzano Joseph Walter	Chief Financial Officer	Jan 22 '26	Sale	5.33	18,666	99,507	568,560	Jan 22 08:34 PM
Seshadri Vishwas	Chief Executive Officer	Jan 22 '26	Sale	5.33	69,832	372,267	1,460,408	Jan 22 08:33 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jan 22 '26	Sale	5.33	13,578	72,383	451,134	Jan 22 08:33 PM
Vasanthavada Madhav	Officer	Jan 22 '26	Proposed Sale	5.29	12,610	66,658		Jan 22 04:10 PM
Vazzano Joseph Walter	Officer	Jan 22 '26	Proposed Sale	5.33	18,666	99,507		Jan 22 04:09 PM
O'Malley Brendan M.	Officer	Jan 22 '26	Proposed Sale	5.39	13,578	73,233		Jan 22 04:09 PM
Seshadri Vishwas	Officer	Jan 22 '26	Proposed Sale	5.33	69,832	372,267		Jan 22 04:08 PM
Alvino Mark	Director	Jan 21 '26	Sale	5.23	13,500	70,574	48,752	Jan 21 04:30 PM
Alvino Mark	Director	Jan 21 '26	Proposed Sale	5.23	13,500	70,574		Jan 21 04:10 PM
Seshadri Vishwas	Chief Executive Officer	Dec 29 '25	Sale	5.31	25,000	132,740	1,164,818	Dec 29 04:30 PM
Seshadri Vishwas	Officer	Dec 29 '25	Proposed Sale	5.31	25,000	132,695		Dec 29 04:00 PM
Alvino Mark	Director	Nov 13 '25	Sale	4.74	15,000	71,168	62,252	Nov 14 04:30 PM
Alvino Mark	Director	Nov 13 '25	Proposed Sale	4.74	15,000	71,168		Nov 13 04:06 PM
Seshadri Vishwas	Chief Executive Officer	Oct 16 '25	Sale	5.49	249	1,366	1,189,818	Oct 16 04:15 PM
Seshadri Vishwas	Officer	Oct 16 '25	Proposed Sale	5.49	249	1,366		Oct 16 04:09 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Sep 29 '25	Sale	5.39	9,366	50,516	350,763	Oct 01 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 30 '25	Sale	5.24	25,000	130,930	1,190,067	Oct 01 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 29 '25	Sale	5.39	19,274	103,954	1,215,067	Oct 01 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Sep 29 '25	Sale	5.39	9,035	48,730	453,631	Oct 01 04:30 PM
Seshadri Vishwas	Officer	Sep 29 '25	Proposed Sale	5.39	44,274	238,792		Sep 29 04:54 PM
O'Malley Brendan M.	Officer	Sep 29 '25	Proposed Sale	5.39	9,366	50,516		Sep 29 04:44 PM
Vazzano Joseph Walter	Officer	Sep 29 '25	Proposed Sale	5.39	9,366	50,516		Sep 29 04:31 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Sep 22 '25	Sale	5.43	688	3,736	360,129	Sep 22 07:49 PM
O'Malley Brendan M.	Officer	Sep 22 '25	Proposed Sale	5.86	17,376	101,749		Sep 22 04:23 PM
Crombez Eric	Director	Aug 14 '25	Sale	6.93	4,718	32,683	42,427	Aug 15 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Aug 15 '25	Sale	7.36	15,000	110,358	462,666	Aug 15 04:30 PM
Vazzano Joseph Walter	Officer	Aug 15 '25	Proposed Sale	7.36	15,000	110,358		Aug 15 04:15 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 22 '25	Sale	6.64	1,502	9,975	477,666	Jul 22 04:15 PM
Vazzano Joseph Walter	Officer	Jul 22 '25	Proposed Sale	6.64	1,502	9,975		Jul 22 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABEO

Abeona Therapeutics Inc

Upgrade your Finviz experience